Most Recent
Pfizer, maker of the blockbuster rheumatoid arthritis biologic Enbrel, has taken generic drug maker Sandoz to court for information on its Enbrel biosimilar, after winning a bid for preliminary discovery against Samsung Biopis to pursue a possible infringement case over the same drug.
A class action against the NSW government over a contractor who took private details of 130 ambulance workers to on-sell to personal injury law firms, including Bannister Law, has settled.
Mobility equipment provider Country Care Group will fight for the dismissal of three charges brought by federal prosecutors in the country's first criminal cartel case against an Australian business.
A Federal Court judge has reversed a prior ruling expanding the class in a lawsuit against Johnson & Johnson unit Ethicon over allegedly defective pelvic mesh implants, saying he had "no confidence" new group members would have sufficient opportunity to opt out before judgment is delivered in a few weeks.
An impending judgment in the long-running class action against Johnson & Johnson unit Ethicon over allegedly defective pelvic mesh implants has sent the parties scrambling about opt out notices and the Federal Court considering reversing prior orders that expanded the group definition.
Cosmetic Institute director Dr Eddy Dona has flagged that he may drag insurers of his now collapsed medical chain into a class action brought against him and the company over allegedly botched breast implants.
UK biopharmaceutical company Kymab may attack experiments done by US biotechnology giant Regeneron creating genetically modified mice with splices of human genomes, as it defends its proposed patent for a human rat.
Former health minister and Prime Trust director Michael Wooldridge wants court approval to manage four corporations, despite a recent ruling from the Full Federal Court that reimposed a ban on him and three other former directors of the collapsed retirement village for violations of the Corporations Act.
Agricultural giant Monsanto is facing a class action in Australia over the marketing of its Roundup weedkiller, after being hit with a landmark US$ 2 billion verdict in the United States.
Health insurer Medibank has admitted to engaging in misleading and deceptive conduct when it falsely told consumers they were not eligible for certain coverage under their insurance policies in what it called an "internal process failure", but denies the ACCC's claim that consumers were denied the benefits they paid for.